R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up

被引：2

作者：

Vuolio, Tero ^{[1
,2
,3
]}

Kuittinen, Outi ^{[3
,4
,5
]}

Vayrynen, Juha P. ^{[6
,7
]}

Teppo, Hanna-Riikka ^{[6
,7
]}

Prusil, Roosa E. I. ^{[8
]}

Ramet, Maria ^{[9
]}

Kuitunen, Hanne ^{[10
]}

Paloneva, Timo ^{[11
]}

Kuusisto, Milla E. L. ^{[1
,2
,3
]}

机构：

[1] Univ Oulu, Oulu, Finland

[2] Oulu Univ Hosp, Oulu, Finland

[3] Univ Eastern Finland, Inst Clin Med, Fac Hlth Med, Kuopio, Finland

[4] Oulu Univ Hosp, Dept Oncol & Radiotherapy, Oulu, Finland

[5] Kuopio Univ Hosp, Canc Ctr, Kuopio, Finland

[6] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Dept Pathol, Oulu, Finland

[7] Univ Oulu, Translat Med Res Unit, Oulu, Finland

[8] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland

[9] Lansi Pohja Cent Hosp, Kemi, Finland

[10] Oulu Univ Hosp, Canc Ctr, Oulu, Finland

[11] Cent Ostrobothnian Cent Hosp, Kokkola, Finland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 202卷 / 04期

关键词：

RITUXIMAB; MANAGEMENT; THERAPY; DISEASE; TRIAL;

D O I：

10.1111/bjh.18896

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E24 / E26

页数：3

共 50 条

[1] R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma
Prusila, Roosa Enni Inkeri
Haapasaari, Kirsi-Maria
Marin, Katja
Pollari, Marjukka
Soini, Ylermi
Vornanen, Martine
Karjalainen-Lindsberg, Marja-Liisa
Turpeenniemi-Hujanen, Taina
Kuittinen, Outi
ACTA ONCOLOGICA, 2018, 57 (09) : 1265 - 1267
[2] Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up
Pugliese, Novella
Picardi, Marco
Della Pepa, Roberta
Giordano, Claudia
Muriano, Francesco
Leone, Aldo
Delle Cave, Giuseppe
D'Ambrosio, Alessandro
Marafioti, Violetta
Rascato, Maria Gabriella
Russo, Daniela
Mascolo, Massimo
Pane, Fabrizio
CANCERS, 2021, 13 (08)
[3] Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment
Goel, Anupama
Fan, Wen
Patel, Amit A.
Devabhaktuni, Madhuri
Grossbard, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (04): : 261 - 270
[4] Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma
Eichenauer, Dennis A.
Engert, Andreas
CURRENT OPINION IN ONCOLOGY, 2021, 33 (05) : 395 - 399
[5] The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma
Maeda, Lauren S.
Advani, Ranjana H.
CURRENT OPINION IN ONCOLOGY, 2009, 21 (05) : 397 - 400
[6] Treatment of nodular lymphocyte-predominant Hodgkin lymphoma
Eichenauer, Dennis A.
Eich, Hans Theodor
Engert, Andreas
ONKOLOGIE, 2022, 28 (10): : 908 - 913
[7] Treatment Strategies in Nodular Lymphocyte Predominant Hodgkin Lymphoma
Advani, Ranjana
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S168 - S169
[8] Nodular Lymphocyte Predominant Hodgkin Lymphoma
Lee, Alfred Ian
LaCasce, Ann S.
ONCOLOGIST, 2009, 14 (07): : 739 - 751
[9] Management of nodular lymphocyte-predominant Hodgkin lymphoma
Eichenauer, Dennis A.
Engert, Andreas
HEMATOLOGICAL ONCOLOGY, 2013, 31 : 47 - 50
[10] Management of nodular lymphocyte predominant Hodgkin lymphoma
Advani, Ranjana H.
Hoppe, Richard T.
HEMATOLOGICAL ONCOLOGY, 2015, 33 : 90 - 95

← 1 2 3 4 5 →